Recce Pharmaceuticals Executive Director, James Graham, provides an update on the firm’s clinical pathway and its lead compound RECCE 327.
Disclaimer:
If you own the YouTube channel related to this video and do not want it to be featured here, you can contact us through our contact page. We will gladly remove it without questioning your reason